precocious puberty
Conditions
Interventions
Case series:rhGH therapy
Sponsors
The Children's Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
Female
Age
3 Years to 12 Years
Inclusion criteria
Inclusion criteria: 1. Girls are diagnosed as CPP: secondary sex characteristic appears before age 8, chronological age (CA) > 6 years, Bone age (BA) = 11.5 years, BA > CA for 1 year; GnRH challenge test presents puberty response, gonad enlargement; Ovarian volume in girls under B-ultrasound > 1ml, and multiple follicles with diameters > 4mm can be seen; 2. Girls diagnosed as fast progressive puberty: secondary sex characteristic appears before age 8 years, rapid sexual development, the time from one developmental stage to the next stage is shorter (<6 months); 3. Patients who have not started treatment with GnRHa or rhGH; 4. Agree to accept GnRHa and or rhGH treatment at their own expense (at their own expense); 5. Doctors evaluated children without contraindications to rhGH; 6. Patients or their guardians are able to understand, and voluntarily sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Liver and renal insufficiency (ALT> 2 times the upper limit of normal, Cr> 2 times the upper limit of normal); 2. Hepatitis B virus tests positive for anti-HBc, HBsAg, and HbeAg; 3. Patients known to be highly allergic or allergic to the test drug; 4. Patients with severe cardiopulmonary, hematological and malignant tumors diseases or general infection, immune deficiency; 5. Other types of identified abnormal growth and development: such as Turner syndrome, constitutional delay of growth and puberty, Laron syndrome, growth hormone receptor deficiency, girls of growth retardation without excluding abnormal chromosome; 6. Patients diagnosed with diabetes; 7. Patients who participated in clinical trials of other growth and development-related drugs within 3 months; 8. Researchers believe that patients are not suitable for inclusion in this study; 9. Patients or their guardians do not agree to sign the informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PAH;CV;HtSDSBA;Blood routine;Urine routine;Blood biochemistry;HbA1c;IGF-1;IGFBP-3;Thyroid function;Glandular function;Adrenal function; | — |
Countries
China
Contacts
Public ContactJunfen Fu
The Children's Hospital, Zhejiang University School of Medicine
Outcome results
None listed